How does HupA compare to other acetylcholinesterase inhibitors?
When compared to donepezil and rivastigmine, HupA has been demonstrated to exhibit superior efficacy to existing acetylcholinesterase inhibitors via higher blood brain barrier penetration, better bioavailability, longer duration of action, and minimal peripheral cholinergic side effects at therapeutic doses.
Related Questions
- How does the compatibility of BromMax® to cooling water scale and corrosion inhibitors compare with that of bleach and activated sodium bromide programs?
- Could you explain why toxicity of acetylcholinesterase inhibitors includes both Hypotension and hypertension?
- How does HupA compare to other acetylcholinesterase inhibitors?
